Early diagnostic biomarkers for esophageal adenocarcinoma - The current state of play

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 7, 2013, Pages 1185-1209

  Shah, Alok Kishorkumar ^a   Saunders, Nicholas A ^a   Barbour, Andrew P ^a   Hill, Michelle M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLYCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 375; PROTEOGLYCAN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA;

BARRETT ESOPHAGUS; CHOLESTEROL INTAKE; DNA METHYLATION; ESOPHAGEAL ADENOCARCINOMA; FAT INTAKE; FEEDING BEHAVIOR; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; MASS SCREENING; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SMOKING;

ADENOCARCINOMA; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; HUMANS; INCIDENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880028625     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1415     Document Type: Review

References (215)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 2009;3:S2-5.
4. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009;101:855-9.
5. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in White males. Cancer 2001;92:549-55. (Pubitemid 32735190)
6. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-35.
7. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in Blacks and Whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471-8. (Pubitemid 41642525)
8. Sonnenberg A. Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis 2011;29:229-34.
9. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 2003;76:S1367-9. (Pubitemid 37204779)
10. Revels SL, Morris AM, Reddy RM, Akateh C, Wong SL. Racial disparities in esophageal cancer outcomes. Ann Surg Oncol 2013;20:1136-41.
11. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9. (Pubitemid 44918357)
12. Rutegard M, Lagergren P, Nordenstedt H, Lagergren J. Oesophageal adenocarcinoma: the new epidemic in men? Maturitas 2011;69:244-8.
13. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87-101.
14. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:872-8. (Pubitemid 43823511)
15. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1055-62. (Pubitemid 32959152)
16. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-32. (Pubitemid 32807718)
17. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000;95:387-94. (Pubitemid 30106166)
18. Tischoff I, Tannapfel A. Barrett's esophagus: can biomarkers predict progression to malignancy? Expert Rev Gastroenterol Hepatol 2008; 2:653-63.
19. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus G. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
20. Oh DS, Demeester SR. Pathophysiology and treatment of Barrett's esophagus. World J Gastroenterol 2010;16:3762-72.
21. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303-21. (Pubitemid 30137118)
22. Oberg S, Johansson J, Wenner J, Walther B. Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Ann Surg 2002;235:338-45. (Pubitemid 34183884)
23. American Gastroenterological AssociationSpechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
24. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006;55:442.
25. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc 2003;58:661-70. (Pubitemid 37370477)
26. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001; 96:2005-12. (Pubitemid 32660890)
27. Wang KK, Sampliner REPractice Parameters Committee of the American College of G. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97. (Pubitemid 351406009)
28. Spechler SJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2005;100:927-35. (Pubitemid 40592389)
29. Incarbone R, Bonavina L, Saino G, Bona D, Peracchia A. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002;16:263-6. (Pubitemid 34112973)
30. Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg 2002;6:29-35.
31. Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004;91:997-1003. (Pubitemid 39070814)
32. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40. (Pubitemid 34173814)
33. Downs-Kelly E, Mendelin JE, Bennett AE, Castilla E, Henricks WH, Schoenfield L, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol 2008;103:2333-40.
34. Moyes LH, Going JJ. Still waiting for predictive biomarkers in Barrett's oesophagus. J Clin Pathol 2011;64:742-50.
35. Collard JM. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am 2002;12:77-92.
36. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33. (Pubitemid 34049191)
37. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91. (Pubitemid 29063449)
38. Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med 2011;5:397-404.
39. Hirst NG, Gordon LG, Whiteman DC, Watson DI, Barendregt JJ. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol 2011;26:247-54.
40. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
41. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009;28:177-83.
42. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61. (Pubitemid 32717537)
43. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009;69:4112-5.
44. Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, et al. Threetiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE 2008;3:e1890.
45. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9:2912-9. (Pubitemid 36993249)
46. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006;4:701-8. (Pubitemid 43825806)
47. 2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996;93:7081-4.
48. Fang M, Lew E, Klein M, Sebo T, Su Y, Goyal R. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. Am J Gastroenterol 2004;99:1887-94. (Pubitemid 39421229)
49. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76. (Pubitemid 30485000)
50. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998;153:287-94. (Pubitemid 28317532)
51. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007;4:e67.
52. Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 2003;125:1121-31. (Pubitemid 36644890)
53. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006;55:1390-7. (Pubitemid 44476779)
54. Walch AK, Zitzelsberger HF, Bruch J, Keller G, Angermeier D, Aubele MM, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000;156:555-66. (Pubitemid 30643811)
55. Lai LA, Paulson TG, Li X, Sanchez CA, Maley C, Odze RD, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 2007;46:532-42. (Pubitemid 46649568)
56. Riegman PH, Vissers KJ, Alers JC, Geelen E, Hop WC, Tilanus HW, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61:3164-70. (Pubitemid 32691970)
57. Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res 2008;1:413-23.
58. Wiech T, Nikolopoulos E, Weis R, Langer R, Bartholome K, Timmer J, et al. Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest 2009;89:385-97.
59. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2008;68:4163-72.
60. Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL, et al. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009;15:3305-14.
61. Robertson EV, Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. Am J Gastroenterol 2008;103:443-9. (Pubitemid 351248711)
62. The Esophageal Adenocarcinoma Genetics C, The Wellcome Trust Case Control CSu Z, Gay LJ, Strange A, Palles C, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012;44:1131-6.
63. Wu IC, Zhao Y, Zhai R, Liu G, Ter-Minassian M, Asomaning K, et al. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia 2011;13:386-92.
64. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905.
65. Streppel MM, Lata S, Delabastide M, Montgomery EA, Wang JS, Canto MI, et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene. 2013 Jan 14. [Epub ahead of print].
66. Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2013 Jan 16. [Epub ahead of print].
67. Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 2010;16:5824-34.
68. Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, et al. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects. J Physiol Pharmacol 2010;61:409-18.
69. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96. (Pubitemid 30140846)
70. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000;6:135-8. (Pubitemid 30064985)
71. Kuramochi H, Vallbohmer D, Uchida K, Schneider S, Hamoui N, Shimizu D, et al. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg 2004;8:1007-16.
72. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclo-oxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6. (Pubitemid 32319127)
73. Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003;42:457-65. (Pubitemid 36605588)
74. Allameh A, Rasmi Y, Nasseri-Moghaddam S, Tavangar SM, Sharifi R, Sadreddini M. Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects. Cancer Epidemiol 2009;33:79-84.
75. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34. (Pubitemid 28335064)
76. Prins MJ, Verhage RJ, ten Kate FJ, van Hillegersberg R. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg 2012;16:956-66.
77. Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, et al. Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer 2006;6:134.
78. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NFkappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25:317-23. (Pubitemid 38344397)
79. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005;100:1257-64. (Pubitemid 40904346)
80. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239:491-500. (Pubitemid 38372765)
81. Abdel-Latif MM, O'Riordan JM, Ravi N, Kelleher D, Reynolds JV. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis Esophagus 2005;18:246-52. (Pubitemid 43904793)
82. Jenkins GJ, Mikhail J, Alhamdani A, Brown TH, Caplin S, Manson JM, et al. Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J Clin Pathol 2007;60:1232-7. (Pubitemid 350084544)
83. Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, Ten Brinke A, et al. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol 2008;68:616-23.
84. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006;95:1568-75. (Pubitemid 44863361)
85. Dvorak K, Chavarria M, Payne CM, Ramsey L, Crowley-Weber C, Dvorakova B, et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res 2007;13:5305-13. (Pubitemid 47510354)
86. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 2012;25:242-9.
87. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61. (Pubitemid 28320046)
88. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001;85:383-92. (Pubitemid 32747707)
89. Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber C, Hofelmayr A, et al. MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 2010;8:99.
90. El-Kenawy Ael M, Lotfy M, El-Kott A, El-Shahat M. Significance of matrix metalloproteinase 9 and CD34 expressions in esophageal carcinoma: correlation with DNA content. J Clin Gastroenterol 2005;39:791-4. (Pubitemid 41361897)
91. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 2007;13:676-82.
92. Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Laudanski J, et al. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol 2008;46:471-8.
93. Darnton SJ, Hardie LJ, Muc RS, Wild CP, Casson AG. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer 2005;115: 351-8. (Pubitemid 40663737)
94. Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21. (Pubitemid 30660591)
95. Shi XY, Bhagwandeen B, Leong AS. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl Immunohistochem Mol Morphol 2008;16:447-52.
96. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neugene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35-9. (Pubitemid 30054384)
97. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-67. (Pubitemid 46233226)
98. Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 2003;16:17-23. (Pubitemid 36603489)
99. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20:2971-9. (Pubitemid 34728892)
100. Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, et al. Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma. World J Surg 2004;28:675-9. (Pubitemid 39097124)
101. Kerkhof M, Kusters JG, van Dekken H, Kuipers EJ, Siersema PD. Biomarkers for risk stratification of neoplastic progression in Barrett esophagus. Cell Oncol 2007;29:507-17. (Pubitemid 350136505)
102. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54. (Pubitemid 24014542)
103. Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 2009;62:771-6.
104. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008;135:255-60.
105. Smith CM, Watson DI, Leong MP, Mayne GC, Michael MZ, Wijnhoven BP, et al. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol 2011;17:1036-44.
106. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 2008;27:6667-78.
107. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 2009;174:1940-8.
108. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008;68:10094-104.
109. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010;97:853-61.
110. Bansal A, Lee IH, Hong X, Anand V, Mathur SC, Gaddam S, et al. Feasibility of microRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011;106:1055-63.
111. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15:6192-200.
112. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009;15:5744-52.
113. Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, et al. EP300 - a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 2010;126:114-24.
114. Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011;129:1661-70.
115. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 2012;26:1287-99.
116. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012;32:326-48.
117. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol 2012;13:448-62.
118. Kim EH, Misek DE. Glycoproteomics-based identification of cancer biomarkers. Int J Proteomics 2011; 2011:601937.
119. Fanayan S, Hincapie M, Hancock WS. Using lectins to harvest the plasma/serum glycoproteome. Electrophoresis 2012;33:1746-54.
120. Ongay S, Boichenko A, Govorukhina N, Bischoff R. Glycopeptide enrichment and separation for protein glycosylation analysis. J Sep Sci 2012;35:2341-72.
121. Shimamoto C, Weinstein WM, Boland CR. Glycoconjugate expression in normal, metaplastic, and neoplastic human upper gastrointestinal mucosa. J Clin Invest 1987;80:1670-8. (Pubitemid 18007140)
122. Poorkhalkali N, Jacobson I, Helander HF. Lectin histochemistry of the esophagus in several mammalian species. Anat Embryol (Berl) 1999;200:541-9. (Pubitemid 29467317)
123. Neumann H, Wex T, Monkemuller K, Vieth M, Fry LC, Malfertheiner P. Lectin UEA-I-binding proteins are specifically increased in the squamous epithelium of patients with Barrett's esophagus. Digestion 2008;78:201-7.
124. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, O'Donovan M, Novelli M, Lovat LB, et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med 2012;18:315-21.
125. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, et al. Population-based study reveals new risk-stratification biomarker panel for barrett's esophagus. Gastroenterology 2012;143:927-35.
126. Byrne AM, Sharma R, Duggan G, Kelleher D, Long A. Deoxycholic acid impairs glycosylation and fucosylation processes in esophageal epithelial cells. Glycobiology 2012;22:638-48.
127. Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma. PLoS ONE 2011; 6:e22513.
128. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904. (Pubitemid 39383039)
129. Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treat Rev 2011;37:579-89.
130. Zhai R, Zhao Y, Su L, Cassidy L, Liu G, Christiani DC. Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia 2012;14:29-33.
131. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
132. Hoffmann AC, Vallbohmer D, Prenzel K, Metzger R, Heitmann M, Neiss S, et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 2009;135:1231-7.
133. Chen ST, Pan TL, Juan HF, Chen TY, Lin YS, Huang CM. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res 2008;7:1379-87.
134. Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011;71:5090-100.
135. Mechref Y, Hussein A, Bekesova S, Pungpapong V, Zhang M, Dobrolecki LE, et al. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res 2009;8:2656-66.
136. Mitra I, Zhuang Z, Zhang Y, Yu CY, Hammoud ZT, Tang H, et al. Nglycan profiling by microchip electrophoresis to differentiate disease states related to esophageal adenocarcinoma. Anal Chem 2012;84:3621-7.
137. Gaye MM, Valentine SJ, Hu Y, Mirjankar N, Hammoud ZT, Mechref Y, et al. Ion mobility-mass spectrometry analysis of serum N-linked glycans from esophageal adenocarcinoma phenotypes. J Proteome Res 2012;11:6102-10.
138. Mann B, Madera M, Klouckova I, Mechref Y, Dobrolecki LE, Hickey RJ, et al. A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis 2010;31:1833-41.
139. Choi E, Loo D, Dennis JW, O'Leary CA, Hill MM. High-throughput lectin magnetic bead array-coupled tandem mass spectrometry for glycoprotein biomarker discovery. Electrophoresis 2011;32:3564-75.
140. Loo D, Jones A, Hill MM. Lectin magnetic bead array for biomarker discovery. J Proteome Res 2010;9:5496-500.
141. Yakoub D, Keun HC, Goldin R, Hanna GB. Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res 2010;70:9129-36.
142. Djukovic D, Baniasadi HR, Kc R, Hammoud Z, Raftery D. Targeted serum metabolite profiling of nucleosides in esophageal adenocarcinoma. Rapid Commun Mass Spectrom 2010;24:3057-62.
143. Zhang J, Bowers J, Liu L, Wei S, Gowda GA, Hammoud Z, et al. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS ONE 2012;7:e30181.
144. Zhang J, Liu L, Wei S, Nagana Gowda GA, Hammoud Z, Kesler KA, et al. Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2011;141:469-75.
145. Davis VW, Schiller DE, Eurich D, Sawyer MB. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol 2012;10:271.
146. Hardie LJ, Darnton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005;217:221-30. (Pubitemid 40023121)
147. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122:1113-21. (Pubitemid 34267292)
148. Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2009;104:2153-60.
149. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic
150. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997;57:2619-22. (Pubitemid 27283770)
151. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9. (Pubitemid 33091623)
152. Vieth M, Schneider-Stock R, Rohrich K, May A, Ell C, Markwarth A, et al. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch 2004;445:135-41. (Pubitemid 39215544)
153. Kempster S, Phillips WA, Baindur-Hudson S, Thomas RJ, Dow C, Rockman SP. Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. Cancer Lett 2000;150:57-62. (Pubitemid 30123048)
154. Baumann S, Keller G, Puhringer F, Napieralski R, Feith M, Langer R, et al. The prognostic impact of O6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer 2006;119:264-8.
155. Kuester D, El-Rifai W, Peng D, Ruemmele P, Kroeckel I, Peters B, et al. Silencing of MGMT expression by promoter hypermethylation in the metaplasia - dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett 2009;275:117-26.
156. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006;25:3084-92. (Pubitemid 43780474)
157. Clement G, Bosman FT, Fontolliet C, Benhattar J. Monoallelic methylation of the APC promoter is altered in normal gastric mucosa associated with neoplastic lesions. Cancer Res 2004;64:6867-73. (Pubitemid 39330993)
158. Peng DF, Razvi M, Chen H, Washington K, Roessner A, Schneider-Stock R, et al. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut 2009;58:5-15.
159. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, et al. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 2005;7:854-61.
160. Gu P, Xing X, Tanzer M, Rocken C, Weichert W, Ivanauskas A, et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008;10:563-72. (Pubitemid 351770300)
161. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, et al. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia 2007;9:236-45. (Pubitemid 46457240)
162. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 2007;13:6293-300. (Pubitemid 350075017)
163. Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, et al. Reprimo methylation is a potential biomarker of Barrett's-associated esophageal neoplastic progression. Clin Cancer Res 2006;12:6637-42. (Pubitemid 44876831)
164. Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, Herman JG, et al. Frequent hypermethylation of the 50 CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 2001;7:2765-9. (Pubitemid 32911382)
165. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, et al. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 2007;56:1047-53. (Pubitemid 47123231)
166. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005;116:584-91. (Pubitemid 41099195)
167. Kaz AM, Luo Y, Dzieciatkowski S, Chak A, Willis JE, Upton MP, et al. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma. Genes Chromosomes Cancer 2012;51:384-93.
168. Guo M, House MG, Akiyama Y, Qi Y, Capagna D, Harmon J, et al. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer 2006;119:2078-83. (Pubitemid 44423664)
169. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 2008;123:2331-6.
170. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, et al. Hypermethylation of the nel-like 1 gene is acommon and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 2007;26:6332-40. (Pubitemid 47462110)
171. Zou H, Osborn NK, Harrington JJ, Klatt KK, Molina JR, Burgart LJ, et al. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005;14:830-4. (Pubitemid 40478544)
172. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev 2008;17:111-7. (Pubitemid 351196280)
173. Moinova H, Leidner RS, Ravi L, Lutterbaugh J, Barnholtz-Sloan JS, Chen Y, et al. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev 2012;21:594-600.
174. Clement G, Guilleret I, He B, Yagui-Beltran A, Lin YC, You L, et al. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 2008;99:46-53. (Pubitemid 350239030)
175. Soutto M, Peng D, Razvi M, Ruemmele P, Hartmann A, Roessner A, et al. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer 2010;116:4033-42.
176. Peng D, Hu TL, Jiang A, Washington MK, Moskaluk CA, Schneider-Stock R, et al. Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas. PLoS ONE 2011;6:e22009.
177. Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, et al. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer 2008;7:75.
178. Kaz AM, Wong CJ, Luo Y, Virgin JB, Washington MK, Willis JE, et al. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 2011;6:1403-12.
179. Alvi MA, Liu X, O'Donovan M, Newton R, Wernisch L, Shannon NB, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013;19:878-88.
180. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol 2006;208:100-7. (Pubitemid 43025708)
181. van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, et al. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 2005;129:1274-81. (Pubitemid 41446866)
182. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, et al. Expression analysis of Barrett's esophagus-associated highgrade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 2008;14:6440-8.
183. Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010;139:1995-2004.
184. Ostrowski J, Mikula M, Karczmarski J, Rubel T, Wyrwicz LS, Bragoszewski P, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med (Berl) 2007;85:733-43. (Pubitemid 47063526)
185. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, Gilhuijs-Pederson LA, Ten Kate FJ, Reitsma PH, et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol 2008;15:3459-70.
186. van Dekken H, Vissers K, Tilanus HW, Kuo WL, Tanke HJ, Rosenberg C, et al. Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet 2006;166:157-62.
187. Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T, et al. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. Int J Cancer 2009;125:2349-59.
188. Greenawalt DM, Duong C, Smyth GK, Ciavarella ML, Thompson NJ, Tiang T, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer 2007;120:1914-21. (Pubitemid 46418367)
189. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Genomewide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res 2010;3:1176-86.
190. Kim SM, Park YY, Park ES, ChoJY, Izzo JG, Zhang D, et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS ONE 2010;5:e15074.
191. van Dekken H, Tilanus HW, Hop WC, Dinjens WN, Wink JC, Vissers KJ, et al. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet 2009;189:37-42.
192. Lai LA, Kostadinov R, Barrett MT, Peiffer DA, Pokholok D, Odze R, et al. Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res 2010;8:1084-94.
193. van Duin M, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, et al. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res 2007;118:130-7. (Pubitemid 350125249)
194. Xu Y, Selaru FM, Yin J, Zou TT, Shustova V, Mori Y, et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res 2002;62:3493-7. (Pubitemid 34651397)
195. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 2005;65:3146-54. (Pubitemid 40524595)
196. Barrett MT, Yeung KY, Ruzzo WL, Hsu L, Blount PL, Sullivan R, et al. Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae. Neoplasia 2002;4:121-8. (Pubitemid 34218680)
197. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006;25:3346-56. (Pubitemid 43846319)
198. Hammoud ZT, Badve S, Zhao Q, Li L, Saxena R, Thorat MA, et al. Differential gene expression profiling of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2009;137:829-34.
199. Gomes LI, Esteves GH, Carvalho AF, Cristo EB, Hirata R Jr, Martins WK, et al. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res 2005;65:7127-36. (Pubitemid 41161242)
200. Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology 2006;131:925-33. (Pubitemid 44307058)
201. Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, et al. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 2004;23:4780-8. (Pubitemid 38859466)
202. Lao-Sirieix P, Boussioutas A, Kadri SR, O'Donovan M, Debiram I, Das M, et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009;58:1451-9.
203. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 2011;60:1317-26.
204. Rao S, Welsh L, Cunningham D, te-Poele RH, Benson M, Norman A, et al. Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer. Clin Colorectal Cancer 2011;10:48-56.
205. Schauer M, Janssen KP, Rimkus C, Raggi M, Feith M, Friess H, et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res 2010;16:330-7.
206. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 2007;13:912-9. (Pubitemid 46340367)
207. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-67. (Pubitemid 46628468)
208. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006;24:3789-98. (Pubitemid 46628477)
209. Luzna P, Gregar J, Uberall I, Radova L, Prochazka V, Ehrmann J Jr. Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol 2011;6:114.
210. Leidner RS, Ravi L, Leahy P, Chen Y, Bednarchik B, Streppel M, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012;51:473-9.
211. Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg 2011;91:1523-30.
212. Revilla-Nuin B, Parrilla P, Lozano J, Martinez de Haro LF, Ortiz A, Martinez C, et al. Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg 2013;257:886-93.
213. Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63.
214. Hummel R, Hussey DJ, Michael MZ, Haier J, Bruewer M, Senninger N, et al. MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol 2011;18:253-60.
215. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 2011;128:132-43.